Following the previous work, we present here safety and efficacy data from an expansion cohort of 10 patients with advanced, anti-PD-1-resistant melanoma treated with the previously established combination regimen ziv-aflibercept and pembrolizumab. Here, PDCD1 is linked to melanoma.